Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Medicare said Abbott can sell its new diabetes device. Photo: Daniel Acker / Bloomberg via Getty
Abbott Laboratories received federal approval today to start selling its new glucose monitoring system to diabetes patients with Medicare coverage. Medicare's approval came almost a year earlier than Wall Street expected, driving down the stock price of competing diabetes device maker Dexcom by about 10%.
Why it matters: The new devices allow people with diabetes to track their blood sugar without having to prick their fingers all the time. A lot of money also is on the line. Medicare pays about $3,000 a year for the new systems, and Abbott intends to market its device aggressively to the 1 in 5 seniors who have diabetes.